NCT04325191

Brief Summary

Increased dietary sodium causes increases in oxidative stress and damages blood vessels. Americans eat more than the recommended amount of sodium. Melatonin is a powerful endogenous antioxidant that has reduced oxidative stress levels in clinical and healthy populations. This study will investigate whether melatonin can attenuate the negative effects of sodium on blood vessels.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 12, 2020

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

March 19, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 27, 2020

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

April 28, 2021

Status Verified

April 1, 2021

Enrollment Period

2.3 years

First QC Date

March 19, 2020

Last Update Submit

April 27, 2021

Conditions

Keywords

Vascular HealthMelatoninDietary SodiumBlood Pressure

Outcome Measures

Primary Outcomes (2)

  • Conduit artery endothelial-dependent function

    Assessed by brachial artery flow mediated dilation (FMD)

    Day 10

  • Microvascular function

    Assessed by Near Infrared Spectroscopy (NIRS)

    Day 10

Secondary Outcomes (1)

  • Blood pressure reactivity

    Day 10

Study Arms (2)

High Salt and Melatonin

EXPERIMENTAL

Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with 10 mg (single dose) of melatonin at night.

Dietary Supplement: Melatonin

High Salt and Placebo

PLACEBO COMPARATOR

Subjects will consume sodium pills throughout the day achieving a total of 6900 mg sodium/day (4600 mg of sodium from pills and 2300 mg from diet) and will supplement with a lactose placebo (single dose) at night.

Other: Placebo

Interventions

MelatoninDIETARY_SUPPLEMENT

Daily consumption of a high sodium diet and melatonin for 10 days

High Salt and Melatonin
PlaceboOTHER

aily consumption of a high sodium diet and placebo for 10 days

High Salt and Placebo

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • healthy
  • normal blood pressure

You may not qualify if:

  • hypertension
  • heart disease
  • diabetes
  • kidney disease
  • renal impairment
  • cancer
  • obese (BMI ≥30)
  • sleep disorder
  • use of tobacco products
  • pregnant or breastfeeding
  • take any medications for the above conditions
  • endurance trained athletes
  • night shift worker
  • melatonin or antioxidant consumption for the previous 3 months
  • use of selective serotonin reuptake inhibitors

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Delaware

Newark, Delaware, 19711, United States

RECRUITING

MeSH Terms

Interventions

Melatonin

Intervention Hierarchy (Ancestors)

TryptaminesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Shannon L Lennon, PhD

    University of Delaware

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Macarena Ramos Gonzalez, MS

CONTACT

Shannon L Lennon, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Participant will not know if they are receiving the melatonin or placebo pills.
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: This is a randomized crossover design trial.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 19, 2020

First Posted

March 27, 2020

Study Start

March 12, 2020

Primary Completion

June 30, 2022

Study Completion

September 30, 2022

Last Updated

April 28, 2021

Record last verified: 2021-04

Locations